Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Peripheral blood cells are increasingly used in place of bone marrow as a source of hematopoietic stem cells for allogeneic transplantation. The relative efficacy of these 2 approaches is unknown. This retrospective multivariate analysis compared results of 288 HLA-identical sibling blood stem cell transplantations with results of 536 HLA-identical sibling bone marrow transplantations. No transplants were T-cell depleted. Median follow-up was 12 months, and analyses focused on 1-year outcomes. Recipients of blood stem cell transplants had more rapid recovery of neutrophils to at least 0.5 x 10(9)/L (median time to recovery, 14 days, compared with 19 days for marrow transplants; P <.001) and of platelets to at least 20 x 10(9)/L (median time, 18 days, compared with 25 days for marrow transplants; P <.001). There was no significant difference in the incidence of grades II to IV acute graft versus host disease (GVHD). The incidence of chronic GVHD was significantly higher after blood stem cell transplantation (1-year probability [95% confidence interval], 65% [56%-72%] compared with 53% [47%-59%]; P =.02) Relapse incidence in the 2 transplant groups did not differ significantly. Treatment-related mortality rates were lower and leukemia-free survival rates were higher with blood stem cell transplants in patients with advanced leukemia (acute leukemia in second remission or chronic myelogenous leukemia in accelerated phase) but not in early leukemia (acute leukemia in first remission or chronic myelogenous leukemia in chronic phase). The median time from transplantation to hospital discharge was 23 days after blood stem cell transplantation and 28 days after bone marrow transplantation (P =.003). Further study with longer follow-up is necessary to definitively establish the role of blood stem cells for allogeneic transplantation, especially in patients with good-risk disease. (Blood. 2000;95:3702-3709)

[1]  R. Storb,et al.  Allogeneic peripheral blood stem cell transplantation. , 2001, Reviews in clinical and experimental hematology.

[2]  N. Ueno,et al.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. , 1999, Blood.

[3]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1997 , 1999, Bone Marrow Transplantation.

[4]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[5]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1996 , 1998, Bone Marrow Transplantation.

[6]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[7]  V. Vitale,et al.  Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. , 1998, Experimental hematology.

[8]  M. Bishop,et al.  Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies , 1998, Bone Marrow Transplantation.

[9]  K. Sullivan,et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.

[10]  A. Elmaagacli,et al.  Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. , 1997, Blood.

[11]  N. Schmitz,et al.  Allogeneic blood stem cell transplantation: considerations for donors. , 1997, Blood.

[12]  J. Klein,et al.  Survival Analysis: Techniques for Censored and Truncated Data , 1997 .

[13]  D. Blaise,et al.  Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.

[14]  J. Armitage,et al.  Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1995 , 1997, Bone Marrow Transplantation.

[16]  N. Schmitz,et al.  Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Garcia-conde,et al.  High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. , 1997, Haematologica.

[18]  A. Deisseroth,et al.  Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. , 1996, Transplantation.

[19]  N. Schmitz,et al.  Transplantation of peripheral blood progenitor cells from HLA‐identical sibling donors , 1996, British journal of haematology.

[20]  R. Storb,et al.  Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.

[21]  N. Schmitz,et al.  PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. , 1996, Bone marrow transplantation.

[22]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[23]  T. Spitzer.  Allogeneic peripheral blood stem cell transplantation. , 1996, The Journal of infusional chemotherapy.

[24]  R. Storb,et al.  Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor , 1996, Stem cells.

[25]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[26]  M. Andreeff,et al.  Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.

[27]  D. Huhn,et al.  Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[29]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[30]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[31]  A. Rimm,et al.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. , 1990, Blood.

[32]  D. Weisenburger,et al.  Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. , 1989, Bone marrow transplantation.

[33]  A. Gratwohl,et al.  Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. , 1989, Bone marrow transplantation.

[34]  J. Chessells,et al.  Bone marrow transplantation for leukaemia. , 1988, Archives of disease in childhood.

[35]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .